107
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Case Report: A Rare Case of Primary Angiosarcoma of the Cervix with a Literature Review

, , ORCID Icon &
Pages 265-271 | Received 11 Sep 2023, Accepted 22 Jan 2024, Published online: 12 Feb 2024

References

  • Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11(10):983–991. doi:10.1016/S1470-2045(10)70023-1
  • Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GFA. A report of 67 patients and a review of the literature. Cancer. 1996;77(11):2400–2406. doi:10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z
  • Pawlik TM, Paulino AF, McGinn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003;98(8):1716–1726. doi:10.1002/cncr.11667
  • Yang OO, Lan T, He JL, et al. Magnetic resonance imaging and contrast-enhanced ultrasound findings of a recurrent primary breast angiosarcoma: a case report. Medicine. 2021;100(5):e24625. doi:10.1097/MD.0000000000024625
  • Shah VI, Gl R, Thompson IW, Sumathi VP, McCluggage WG. Primary angiosarcoma of the cervix: case report of a rare lesion. Int J Gynecol Pathol. 2020;39(1):97–102. doi:10.1097/PGP.0000000000000567
  • Chinczewski L, Taube ET, Feldhaus FW, et al. Angiosarcomas of primary gynecologic origin - a case series and review of the literature. Anticancer Res. 2020;40(10):5743–5750. doi:10.21873/anticanres.14590
  • Ohayi SA, Ezugwu EC, Aderibigbe AS, Udeh EI. Angiosarcoma of the cervix: a case and literature review. Niger J Med. 2013;22(4):362–364.
  • Gaballah AH, Jensen CT, Palmquist S, et al. Angiosarcoma: clinical and imaging features from head to toe. Br J Radiol. 2017;90(1075):20170039. doi:10.1259/bjr.20170039
  • Ohsawa M, Naka N, Tomita Y, Kawamori D, Kanno H, Aozasa K. Use of immunohistochemical procedures in diagnosing angiosarcoma. evaluation of 98 cases. Cancer. 1995;75(12):2867–2874. doi:10.1002/1097-0142(19950615)75:12<2867::aid-cncr2820751212>3.0.co;2-8
  • Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97(1):74–81. doi:10.1002/jso.20766
  • Hashimoto M, Ohsawa M, Ohnishi A, et al. Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab Invest. 1995;73(6):859–863.
  • Fujimoto M, Kiyosawa T, Murata S, et al. Vascular endothelial growth factor in angiosarcoma. Anticancer Res. 1998;18(5B):3725.
  • Lee CH, Marino-Enriquez A, Ou W, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36(5):641–653. doi:10.1097/PAS.0b013e31824a7b1a
  • Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143(Suppl 2):51–58. doi:10.1002/ijgo.12613
  • Alkanat NE, Uner A, Usubutun A. High-grade endometrial stromal sarcoma: morphologic and clinical features, the role of immunohistochemistry and fluorescence in situ hybridization in diagnosis. Int J Surg Pathol. 2022;10668969221098087. doi:10.1177/10668969221098087
  • Hung YP, Fletcher CD, Hornick JL. FOSB is a useful diagnostic marker for pseudomyogenic hemangioendothelioma. Am J Surg Pathol. 2017;41(5):596–606. doi:10.1097/PAS.0000000000000795
  • Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11(3):241–247. doi:10.1097/00130404-200505000-00011
  • Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14(6):1953–1967. doi:10.1245/s10434-006-9335-y
  • Liu H, Zhang H, Zhang C, et al. Pan-soft tissue sarcoma analysis of the incidence, survival, and metastasis: a population-based study focusing on distant metastasis and lymph node metastasis. Front Oncol. 2022;12:890040. doi:10.3389/fonc.2022.890040
  • Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data; Sarcoma meta-analysis collaboration. Lancet. 1997;350(9092):1647–1654.
  • Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008;44(16):2433–2436. doi:10.1016/j.ejca.2008.07.037
  • Budd GT. Management of angiosarcoma. Curr Oncol Rep. 2002;4(6):515–519. doi:10.1007/s11912-002-0066-3
  • Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269–5274. doi:10.1200/JCO.2008.17.3146
  • Lahat G, Dhuka AR, Lahat S, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009;16(9):2502–2509. doi:10.1245/s10434-009-0569-3
  • Asmane I, Litique V, Heymann S, et al. Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature. Anticancer Res. 2008;28(5B):3041.
  • Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104(2):361–366. doi:10.1002/cncr.21140